518044-41-2 Usage
Description
Mal-PEG4-Acid is a PEG (polyethylene glycol) linker that features a maleimide group and a terminal carboxylic acid. This molecule is designed to enhance solubility in aqueous environments due to its hydrophilic PEG spacer. The maleimide group within Mal-PEG4-Acid is capable of forming a covalent bond with a thiol group, which allows for the attachment of biomolecules with a thiol to the PEG linker. Additionally, the terminal carboxylic acid can react with primary amine groups in the presence of certain activators, such as EDC or HATU, to create a stable amide bond.
Uses
Used in Bioconjugation:
Mal-PEG4-Acid is used as a bioconjugation agent for the attachment of biomolecules with a thiol group to a PEG linker. The maleimide group reacts with the thiol group to form a stable covalent bond, which can be useful in various applications, such as drug delivery, protein modification, and the creation of multivalent bioconjugates.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Mal-PEG4-Acid is used as a component in drug delivery systems. The PEG linker can be attached to drug molecules, enhancing their solubility, stability, and circulation time in the body. The maleimide group allows for the covalent attachment of drug molecules with a thiol group, while the terminal carboxylic acid can be used to attach other functional groups or molecules, such as targeting ligands or imaging agents, to improve the drug's specificity and efficacy.
Used in Protein Modification:
In the field of biotechnology, Mal-PEG4-Acid is used as a protein modification agent. The maleimide group can react with a cysteine residue in a protein, allowing for the attachment of the PEG linker to the protein. This modification can improve the protein's stability, solubility, and resistance to proteolytic degradation, which can be beneficial for therapeutic proteins or proteins used in research applications.
Used in Diagnostics:
Mal-PEG4-Acid can be utilized in the development of diagnostic tools, such as imaging agents or biosensors. The PEG linker can be attached to a detection molecule, such as a fluorescent dye or a radioactive isotope, and the maleimide group can be used to attach a targeting molecule, such as an antibody or a peptide, to the detection molecule. This allows for the specific detection and localization of target molecules or cells in biological samples.
Used in Material Science:
In the field of material science, Mal-PEG4-Acid can be employed in the development of biocompatible materials and surfaces. The PEG linker can be used to modify surfaces or materials, such as nanoparticles or hydrogels, to improve their biocompatibility, reduce non-specific protein adsorption, and enhance their stability in biological environments. The maleimide group and terminal carboxylic acid can be used to attach other functional groups or biomolecules to the material, tailoring its properties for specific applications.
Check Digit Verification of cas no
The CAS Registry Mumber 518044-41-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,1,8,0,4 and 4 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 518044-41:
(8*5)+(7*1)+(6*8)+(5*0)+(4*4)+(3*4)+(2*4)+(1*1)=132
132 % 10 = 2
So 518044-41-2 is a valid CAS Registry Number.
518044-41-2Relevant articles and documents
CRYPTOPHYCIN-BASED ANTIBODY-DRUG CONJUGATES WITH NOVEL SELF-IMMOLATIVE LINKERS
-
Page/Page column 21, (2016/10/04)
The present invention relates to antibody- or peptide-drug conjugate compounds where one or more cryptophycin derivatives (macrocyclic depsipeptide) are covalently attached by a self-immolative linker which binds to one or more tumor-associated antigens or cell-surface receptors. The linker contains a cleavage site for proteases and a dipeptide unit able to form a diketopiperazine. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders, such as immune or infective diseases.
